GlaxoSmithKline, Sanofi Team Up for Coronavirus Vaccine
April 14 2020 - 11:14AM
Dow Jones News
By Denise Roland
Sanofi SA and GlaxoSmithKline PLC are joining forces to develop
a coronavirus vaccine in a collaboration that -- if successful --
could pump out hundreds of millions of doses by the second half of
2021.
The partnership -- a first between two major pharmaceutical
companies to fight the pandemic -- brings together existing efforts
at the drug giants. It will combine Sanofi's work reviving a
shelved SARS vaccine with Glaxo's expertise in developing
"adjuvants," or ingredients that boost the immune response to a
vaccine.
The collaboration seeks to bypass a big hurdle facing the dozens
of efforts under way at academic laboratories and startups: a lack
of manufacturing capacity that could severely limit the number of
people who could receive any vaccine.
The companies say their combined manufacturing capacity, plus
the potential for an adjuvant to lower the required vaccine dose
per patient, means they could quickly ramp up production if their
candidate is successful. Glaxo, the biggest vaccine maker in the
world by revenue, and Sanofi, the fourth largest, say they could
produce hundreds of millions of doses of vaccine by the second half
of next year.
"The advantages are we both have scale in manufacturing," said
Glaxo Chief Executive Emma Walmsley. "These are both proven
pandemic technologies whether their antigen [the protein that forms
the basis of Sanofi's vaccine] or our adjuvant."
Ms. Walmlsey said Glaxo's pandemic adjuvant was able to
quadruple the number of doses of vaccine it could manufacture for
the H1N1 flu pandemic in 2009. Meanwhile, Sanofi's vaccine is based
on technology already used in its approved flu vaccine.
Still, the challenges of developing a successful vaccine mean
Glaxo and Sanofi -- like all vaccine developers -- face steep odds.
Typically it takes around a decade to develop a new vaccine with
fewer than one in 10 candidates proving themselves in clinical
trials. So far, there are no approved vaccines or treatments for
Covid-19.
"Starting with proven pandemic technologies definitely improves
the odds, " said Roger Connor, who leads Glaxo's vaccines business.
"The world wants to see confirmation that the challenge is being
solved, but as with all research there's risk involved with
this."
The companies didn't disclose the commercial terms of their
partnership.
Glaxo and Sanofi lag some of the smaller players in the fight
against coronavirus. Moderna Inc. is already testing its vaccine in
humans and a vaccine under way at the University of Oxford is to
start human trials within weeks. Glaxo and Sanofi say their vaccine
should reach that stage by the second half of 2020.
Glaxo and Sanofi are also working with smaller companies to
fight the virus. Glaxo is providing adjuvants to several groups,
including Clover Biopharmaceuticals, a Chinese biotech developing a
vaccine. Sanofi is working with Translate Bio, a U.S.-based
biotech, on another potential vaccine.
The rapid spread of Covid-19 around the world means that even if
Glaxo and Sanofi can develop and scale up a product quickly, they
are unlikely to be able to meet global vaccine demand.
"The world is going to need multiple vaccines to deal with the
scale, and some are going to fail through the development process,"
said Mr. Connor. "Multiple shots on goal is exactly the right
approach and across technology as well."
Write to Denise Roland at Denise.Roland@wsj.com
(END) Dow Jones Newswires
April 14, 2020 10:59 ET (14:59 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Aug 2024 to Sep 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2023 to Sep 2024